American Association for Cancer Research: Adagrasib Plus Cetuximab May Provide Clinical Benefit in Patients With KRASG12C-Mutated Colorectal Cancer
April 09, 2024
April 09, 2024
SAN DIEGO, California, April 9 (TNSres) -- The American Association for Cancer Research issued the following news release:
A combination of the KRASG12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRASG12C-mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1 trial presented a . . .
A combination of the KRASG12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRASG12C-mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1 trial presented a . . .